Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Allena PharmaceuticalsGenetic TechnologiesBrickell BiotechMicrobot MedicalPharmaCyte Biotech
SymbolNASDAQ:ALNANASDAQ:GENENASDAQ:BBINASDAQ:MBOTOTCMKTS:PMCB
Price Information
Current Price$1.12$3.87$0.84$7.55$0.02
52 Week RangeBuyN/ABuyBuyN/A
MarketRank™
Overall Score1.30.41.51.30.5
Analysis Score3.40.03.53.50.0
Community Score2.61.91.32.82.4
Dividend Score0.00.00.00.00.0
Ownership Score0.00.01.70.00.0
Earnings & Valuation Score0.60.01.30.00.0
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyN/A
Consensus Price Target$10.40N/A$5.50$20.00N/A
% Upside from Price Target828.57% upsideN/A551.58% upside164.90% upsideN/A
Trade Information
Market Cap$63.77 million$58.16 million$56.50 million$53.67 million$39.36 million
Beta2.392.650.343.980.49
Average Volume2,083,0101,985,0583,556,001162,59316,414,969
Sales & Book Value
Annual RevenueN/A$10,000.00$7.92 millionN/AN/A
Price / SalesN/A5,815.847.13N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.73 per share$0.65 per share$0.97 per share$5.02 per shareN/A
Price / BookN/A5.950.87N/AN/A
Profitability
Net Income$-47,340,000.00$-4,090,000.00$-23,880,000.00$-7,250,000.00$-3,830,000.00
EPS($2.10)N/A($5.11)N/AN/A
Trailing P/E RatioN/A0.00N/A0.000.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-990.67%N/AN/A
Return on Equity (ROE)-207.07%N/A-187.45%-28.95%-57.82%
Return on Assets (ROA)-112.21%N/A-114.85%-26.60%-49.63%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.54%0.02%N/AN/AN/A
Current Ratio7.99%10.88%3.50%29.32%5.92%
Quick Ratio7.99%10.81%3.50%29.32%5.92%
Ownership Information
Institutional Ownership Percentage28.03%1.39%5.93%9.47%0.02%
Insider Ownership Percentage22.80%N/A10.30%8.69%N/A
Miscellaneous
Employees41N/A13104
Shares Outstanding56.94 million15.03 million66.93 million7.11 million2.39 billion
Next Earnings Date5/12/2021 (Estimated)N/A5/12/2021 (Estimated)5/21/2021 (Estimated)8/12/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
PharmaCyte Biotech Successfully Completes 1 Year Stability StudyPharmaCyte Biotech Successfully Completes 1 Year Stability Study
finance.yahoo.com - April 1 at 10:06 AM
PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Short Interest UpdatePharmaCyte Biotech, Inc. (OTCMKTS:PMCB) Short Interest Update
americanbankingnews.com - March 27 at 5:46 PM
PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial ProductPharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product
finance.yahoo.com - January 26 at 1:20 PM
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial ProductPharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
finance.yahoo.com - December 14 at 10:43 AM
PharmaCyte Biotech Successfully Completes 9-Month Stability StudyPharmaCyte Biotech Successfully Completes 9-Month Stability Study
finance.yahoo.com - December 2 at 6:28 PM
FDA places hold on PharmaCytes cell therapy IND for pancreatic cancerFDA places hold on PharmaCyte's cell therapy IND for pancreatic cancer
seekingalpha.com - October 2 at 1:07 PM
PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U.S. FDAPharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U.S. FDA
news.yahoo.com - October 2 at 1:07 PM
PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment PeriodPharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period
finance.yahoo.com - September 23 at 9:18 AM
PharmaCyte Biotech Successfully Completes Six-Month Stability StudyPharmaCyte Biotech Successfully Completes Six-Month Stability Study
finance.yahoo.com - September 14 at 1:21 PM
PharmaCyte Biotech completes second container closure integrity test for CypCaps productPharmaCyte Biotech completes second container closure integrity test for CypCaps product
pharmabiz.com - September 10 at 10:09 AM
PharmaCyte Biotech Successfully Completes Second Container Closure Integrity TestPharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test
finance.yahoo.com - September 8 at 9:12 AM
PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancerPharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer
pharmaceutical-business-review.com - September 3 at 10:23 AM
PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic CancerPharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer
finance.yahoo.com - September 2 at 8:56 AM
PharmaCyte Biotech Appoints Dr. JoséIglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic CancerPharmaCyte Biotech Appoints Dr. JoséIglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer
marketwatch.com - August 10 at 9:57 AM
PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic CancerPharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer
finance.yahoo.com - August 10 at 9:57 AM
FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer TherapyFDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy
finance.yahoo.com - August 5 at 10:44 AM
PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic CancerPharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer
finance.yahoo.com - August 3 at 12:50 PM
PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular TestsPharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests
finance.yahoo.com - July 29 at 9:37 AM
PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer TherapyPharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer Therapy
finance.yahoo.com - July 27 at 1:07 PM
PharmaCyte Biotech Successfully Completes Container Closure Integrity TestPharmaCyte Biotech Successfully Completes Container Closure Integrity Test
finance.yahoo.com - July 13 at 10:30 AM
PharmaCyte Biotech Successfully Completes Three-Month Stability StudyPharmaCyte Biotech Successfully Completes Three-Month Stability Study
finance.yahoo.com - July 8 at 8:22 AM
PharmaCyte Biotechs COVID-19 Test Offers "Pool Testing" Dr. Fauci and White House Coronavirus Task Force Now ConsideringPharmaCyte Biotech's COVID-19 Test Offers "Pool Testing" Dr. Fauci and White House Coronavirus Task Force Now Considering
www.benzinga.com - June 29 at 1:42 PM
PharmaCyte Biotech’s COVID-19 Test Offers “Pool Testing” Dr. Fauci and White House Coronavirus Task Force Now ConsideringPharmaCyte Biotech’s COVID-19 Test Offers “Pool Testing” Dr. Fauci and White House Coronavirus Task Force Now Considering
finance.yahoo.com - June 29 at 8:42 AM
PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical TrialPharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trial
finance.yahoo.com - June 23 at 8:54 AM
PharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial ProductPharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial Product
finance.yahoo.com - June 15 at 8:16 AM
DateCompanyBrokerageAction
10/1/2020Allena PharmaceuticalsB. RileyBoost Price Target
9/10/2020Allena PharmaceuticalsWedbushReiterated Rating
9/10/2020Allena PharmaceuticalsHC WainwrightReiterated Rating
7/15/2020Allena PharmaceuticalsRoth CapitalReiterated Rating
7/15/2020Allena PharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
2/17/2020Allena PharmaceuticalsCredit Suisse GroupReiterated Rating
11/14/2019Allena PharmaceuticalsCowenReiterated Rating
8/28/2020Brickell BiotechLake Street CapitalInitiated Coverage
8/25/2020Brickell BiotechOppenheimerInitiated Coverage
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.